Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program.

Michael S Epstein,Eric D Shah,Parakkal Deepak,Vladimir M Kushnir

doi:10.14309/ajg.0000000000000215

Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program.

Michael S Epstein, Eric D Shah + Show 2 more

https://doi.org/10.14309/ajg.0000000000000215

Copy DOI

Export

Save

Cite

Journal: American Journal of Gastroenterology	Publication Date: Apr 26, 2019
Citations: 1

#Drug Administration's Risk #Mitigation Strategy Program #Administration's Risk #Risk Evaluation Program #Risk Evaluation #Risk Mitigation Strategy #Drug Administration #Food Risk #Evaluation Program #Risk Mitigation

Abstract
Full-Text
Similar Papers

Abstract

Listen

Epstein, Michael S. MD, FACG; Shah, Eric D. MD; Deepak, Parakkal MD, MBBS, MS; Kushnir, Vladimir M. MD, on behalf of the ACG FDA Related Matters Committee Author Information

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: American Journal of Gastroenterology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program.